|
| 中药注射剂治疗心脑血管疾病系统评价/Meta分析的现状研究 |
| Current Status of Systematic Review or Meta analysis on Chinese Herbal Injection in the Treatment of Cardiovascular and Cerebrovascular Diseases |
| |
| DOI： |
| 中文关键词: 系统评价 Meta分析 心脑血管疾病 中药注射剂 现状分析 |
| 英文关键词:Systematic reviews Meta analysis Cardiovascular and cerebrovascular diseases Chinese herbal injection Status analysis |
| 基金项目:国家自然科学基金项目（编号：81473547）；教育部高等学校博士学科点专项科研基金项目（编号：20130013120001,20120013130002） |
|
| 摘要点击次数: 1432 |
| 全文下载次数: 1133 |
| 中文摘要: |
| 摘 要 目的：调查临床常用中药注射剂治疗心脑血管疾病系统评价/Meta分析的现状。 方法：检索中国知网(CNKI，1979~2015年)和PubMed(1990~2015年)文献数据库，筛选符合纳入标准的中药注射剂治疗心脑血管疾病的系统评价/Meta分析，提取有关信息,应用Microsoft Office 2010中Excel软件分析，并用AMSTAR和PRISMA量表对其方法学和发表质量进行评价。 结果：纳入中药注射剂治疗心脑血管疾病类系统评价/Meta分析224篇，其中中文215篇，英文9篇，发表数量整体呈增长的趋势。出版刊物涉及93种期刊，其中篇数最多的是《中国中医急症》24篇(11.2%)。涉及中药注射剂30余品种，被评价次数最多的为参麦注射液17次(7.6%)；用于治疗心血管疾病和脑血管疾病的临床评价数量相当。方法学质量、发表质量均以中等水平居多。 结论：系统评价/Meta分析手段已得到较好的应用，为中药注射剂治疗心脑血管疾病临床循证决策提供了依据，但对中药注射剂的安全性问题鲜少涉及。因此，在今后的临床研究中，不仅需要进一步提高系统评价、临床试验水平，而且对中药注射剂治疗心脑血管疾病的有效性与安全性并重。 |
| 英文摘要: |
| ABSTRACT Objective:To find out the current status of systematic review (SR) or Meta analysis (MA) of Chinese herbal injection for treating cardiovascular and cerebrovascular diseases.Methods: Relevant SR and MA were retrieved in China National Knowledge Infrastructure and PubMed from January 1979 to 2015. The ones meeting inclusion criteria were included, and their detail information was extracted and analyzed by the software of Microsoft Office Excel. AMSTAR and PRISMA checklists were used to evaluate the methodological quality and publication quality of the included SR or MA. Results:A total of 224 articles including 215 in Chinese and 9 in English were included, and the number of publications had a significant growth trend. They published in 93 different journals from 2003, and the Journal of Emergency in Traditional Chinese Medicine had published the most, which reached 24 (11.2%) SRs or MAs. The included SR or MA evaluated more than 30 Chinese herbal injections, in which Shenmai injection (7.6%) was the most frequent. The number of SRs or MAs for evaluating the efficacy of cardiovascular disease was equal to that for cerebrovascular disease. And the quality of included SR or MA was majority in middle level in methodological and publication.Conclusion:The method of SR or MA had been well applied in the field of Chinese herbal injection for treating cardiovascular and cerebrovascular diseases to provide evidence based decision making in clinic. However, the security issues of Chinese herbal injection were rarely involved in the included SRs or MAs. Therefore, in the future clinical studies, it not only needed to further improve the level of SR, MA and clinical trials, but also payed equal attention to the effectiveness and safety of Chinese herbal injection in the treatment of cardiovascular and cerebrovascular diseases. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
